The greatest liability concerns are often associated with new products entering the market. Yet the recent scrutiny surrounding Depo-Provera highlights a different challenge for insurers and life sciences companies regarding what happens when new risks emerge around medicines that have been in use for decades.
The contraceptive injection has come under increased scrutiny following studies that identified an association between prolonged use of medroxyprogesterone acetate and an increased risk of meningioma, a typically benign brain tumour. Regulators in Europe and the UK have since updated product information and issued warnings relating to the risk. While regulators have identified an elevated risk among some long-term users, they have also emphasised that the overall risk remains low.
For insurers, however, the significance of the issue extends well beyond a single product.
Sean Burke, healthcare and life sciences practice leader at CFC, said products that have been on the market for many years are often viewed differently from newer therapies.
"From an underwriting perspective, established products are often assumed to have a well-understood risk profile, particularly where they've been in the market for decades with an established safety and regulatory history," he said.
The issue has raised broader questions about how emerging risks are identified, assessed and communicated throughout a product's lifecycle.
Burke noted that litigation emerging in the United States has focused in part on questions around what manufacturers knew, or ought to have known, about potential risks and how those risks were communicated over time.
The case also highlights the importance of post-market monitoring, as a medicine's risk profile can continue to evolve long after regulatory approval.
For liability lawyers, that evolution can create some of the most complex disputes in the sector.
"The central issues are causation and the question of defect," said Charlotte Kelly, partner at Clyde & Co.
More specifically, cases frequently turn on whether a pharmaceutical product actually caused the injuries alleged and whether it can be considered defective under the existing liability framework.
"Safety" in the context of pharmaceuticals is inherently relative, Kelly noted. Regulatory approval may be rigorous, but it does not guarantee that every potential risk has been identified throughout a product's commercial life.
"Causation is often the decisive battleground and inherently complex," added Peter Barnes, legal director at Clyde & Co.
Pharmaceutical claims frequently involve conditions with multiple potential causes, long latency periods and evolving scientific evidence. Courts must weigh epidemiological evidence against individual medical histories, with outcomes often dependent on expert testimony.
For underwriters, the focus extends beyond the existence of a potential side effect.
"From an insurer's perspective, a strong pharmacovigilance framework is critical, as is a company's ability to identify emerging issues, escalate them, and implement changes effectively," Burke said.
The ability to monitor safety signals, document decision-making and respond appropriately to evolving evidence forms an important part of how insurers assess life sciences risks.
At the same time, emerging risks can create uncertainty for insurers themselves.
"Whilst new risks emerging from long-established pharmaceutical products inevitably means for insurers the potential of increased exposure, aggregation risk, and uncertainty around policy triggers and limits, careful wording review is essential," Barnes said.
Claims emerging years after launch can create disputes around policy triggers, exclusions and aggregation, while life sciences companies face growing pressure to align risk management, regulatory compliance and insurance strategies.
Beyond any individual product, insurers are also paying close attention to a broader trend.
"There is a growing reliance on blockbuster APIs as the foundation for multiple new drug applications," Burke said. "That concentration of exposure can ultimately lead to large cohorts of potential claimants emerging from a single underlying active ingredient."
In other words, a safety concern associated with one ingredient can potentially affect multiple products, manufacturers and insurance programmes.
The liability landscape is also becoming more active.
"Without a doubt," Barnes said when asked whether pharmaceutical litigation is likely to increase.
"Increased data transparency, patient awareness, and specialist claimant firms are making it easier to bring claims."
The questions raised by Depo-Provera ultimately point to a broader reality. Even products that have been on the market for decades are not immune from new scrutiny, and as scientific understanding evolves, so too can the risks attached to them.
